Pronađeno: 1-5 / 5 radova

Autori: Barrett Martin

>> Filter: Samo Article i Review

Naslov Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial (Article)
Autori Davies Andrew  Merli Francesco  Mihaljevic Biljana S  Mercadal Santiago  Siritanaratkul Noppadol  Solal-Celigny Philippe  Boehnke Axel  Berge Claude  Genevray Magali  Zharkov Artem  Dixon Mark  Brewster Michael  Barrett Martin  MacDonald David 
Info LANCET HAEMATOLOGY, (2017), vol. 4 br. 6, str. E272-E282
Projekat F Hoffmann-La Roche
Ispravka ISI/Web of Science   Članak   Elečas   Rang časopisa   Citati: ISI/Web of Science   Scopus  
Naslov Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study (Meeting Abstract)
Autori Davies Andrew J  Mihaljevic Biljana S  Mercadal Santiago  Mihaylov Georgi  Leppa Sirpa  Cotting Denise  Veenstra Klaas  Zharkov Artem  Dixon Mark  Barrett Martin  Macdonald David 
Info BLOOD, (2016), vol. 128 br. 22, str. -
Projekat Takeda Pharmaceutical Company Ltd; Mundipharma; GSKGlaxoSmithKline; Karyopharma; Roche Holding; Gilead Sciences; Bayer AG; Pfizer; JanssenJohnson & Johnson USAJanssen Biotech Inc; Mundipharma; CTI Bio Pharma
Ispravka ISI/Web of Science   Članak   Elečas   Rang časopisa   Citati: ISI/Web of Science  
Naslov Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study (Article)
Autori Davies Andrew  Merli Francesco  Mihaljevic Biljana S  Siritanaratkul Noppadol  Solal-Celigny Phillippe  Barrett Martin  Berge Claude  Bittner Beate  Boehnke Axel  McIntyre Christine  MacDonald David 
Info LANCET ONCOLOGY, (2014), vol. 15 br. 3, str. 343-352
Projekat F Hoffmann-La Roche
Ispravka ISI/Web of Science   Članak   Elečas   Rang časopisa   Citati: ISI/Web of Science   Scopus  
Naslov Subcutaneous Rituximab and Chemotherapy Achieves Similar Trough Levels, Safety, and Response as Intravenous Rituximab in First-Line Follicular Lymphoma: Stage 1 Results of the Phase 3 Sabrina Study (Meeting Abstract)
Autori Davies Andrew  Merli Francesco  Mihaljevic Biljana S  Siritanaratkul Noppadol  Solal-Celigny Philippe  Boehnke Axel  Berge Claude  McIntyre Christine  Barrett Martin  Macdonald David 
Info HAEMATOLOGICA, (2013), vol. 98 br. , Suppl. 1, str. 131-132
Ispravka ISI/Web of Science   Elečas   Rang časopisa   Citati: ISI/Web of Science  
Naslov Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334) (Meeting Abstract)
Autori Davies Andrew J  Merli Francesco  Mihaljevic Biljana S  Siritanaratkul Noppadol  Solal-Celigny Philippe  Boehnke Axel  Berge Claude  McIntyre Christine  Barrett Martin  Macdonald David 
Info BLOOD, (2012), vol. 120 br. 21, str. -
Ispravka ISI/Web of Science   Elečas   Rang časopisa   Citati: ISI/Web of Science  
Ispis zapisa u formatu:TXT | BibTeX